Jeffrey B. Kindler - Chairman & Chief Executive Officer Frank D ™Amelio “ Chief Financial Officer, Senior Vice President, Business Operations Mikael Dolsten “ President, BioTherapeutics Research & Development Freda Lewis-Hall “ Senior Vice President, Chief Medical Officer Martin Mackay “ President, PharmaTherapeutics Research & Development Mary McLeod “ Senior Vice President, Human Resources Ian Read “ Group President, Worldwide Biopharmaceutical Businesses Cavan Redmond “ Group President, Diversified Businesses Nat Ricciardi “ President, Manufacturing Bill Ringo “ Senior Vice President, Business Development, Strategy & Innovation Amy Schulman “ Senior Vice President, General Counsel Sally Susman “ Senior Vice President, Chief Communications Officer

In addition to the Executive Leadership Team, Jeff Kindler has established the Executive Compliance Committee, which he will chair. It will include Doug Lankler, who as Chief Compliance Officer reports directly to Mr. Kindler, and Chief Internal Auditor Hugh Donnelly, who reports both to the Audit Committee of the Board of Directors and to Frank D ™Amelio. Also on the Executive Compliance Committee will be Frank D ™Amelio, Ian Read, Cavan Redmond and Amy Schulman.

Pfizer will benefit greatly from the expertise of the Executive Leadership Team, and the diversity of experience it represents, Mr. Kindler said. Our creation of the Executive Compliance Committee will serve as an important addition to our compliance infrastructure, and ensure the dedicated involvement of our senior-most leaders in our continuing efforts to fully integrate compliance and integrity into all that we do at Pfizer.

Pfizer is now in the process of finalizing the decisions related to talent and site matters and will work quickly to effectively implement those decisions. Talent and site decisions are subject to works council and/or union consultations and other legal requirements, as applicable.

Financial Highlights

The acquisition is expected to be accretive to Pfizer ™s adjusted diluted earnings per share1 in the second full year after closing. The transaction is anticipated to yield synergies of approximately $4 billion by the end of 2012. These synergies, which are in addition to the approximately $2 billion in net annual cost savings that we plan to achieve by the end of 2011 apart from the Wyeth acquisition, are expected in selling, informational and administrative functions, research and development, and manufacturing.

Pfizer Inc: Working together for a healthier world?„?

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world ™s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world ™s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer

Wyeth is now a wholly owned subsidiary of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory obligations.

Source: Pfizer Inc.